Summary The exposure of cells to 06-benzyl-N2-acetylguanosine (BNAG) and several guanine derivatives is known to reduce the activity of 06-alkylguanine-DNA alkyltransferase (MGMT) 
Chloroethylnitrosoureas (CENUs) are cancer chemotherapeutic drugs widely used in the treatment of several tumours, in particulars brain, systemic malignancies and melanomas. However, in most neoplasms, the response rate is relatively low after singleagent chemotherapy -about 20% in disseminated melanomas (Lee et al, 1995) . CENUs are bialkylating agents and act through the formation of a chloroethyl cation that is able to react on several nucleophilic sites of the nucleic acids. The main cytotoxic lesion is 06-chloroethylguanine, which is able spontaneously to form covalent cross-links with the complementary DNA strands (Tong et al, 1983; Lemoine et al, 1991) . However, the suicidal DNA repair protein 06-alkylguanine-DNA alkyltransferase (MGMT; EC 2.1.1.63) removes O6-alkylguanine by accepting the alkyl group on the cystein residue of its active site (D'Incalci et al, 1988; Lindahl et al, 1988; Pegg and Byers, 1992) . This protein is responsible for the chemoresistance of tumour cells towards CENUs and methylating agents (Nagane et al, 1992; Mineura et al, 1993; Gerson and Willson, 1995; Pegg et al, 1995) . Its amount in the cell is inversely proportional to the DNA interstrand cross-links frequency and consequently to cell sensitivity to CENUs (Godeneche et al, 1990) . The constitutive level of MGMT in mammals varies considerably from species to species but also from tissue to tissue within the same species (Pegg et al, 1995) . A wide MGMT spectrum has been found in neoplasic tissues: cells that exhibit high MGMT levels have been designated Mer+ (Mer for methyl enzyme repair) and those that are MGMT deficient as Mer-. It has been shown previously that O6-benzylguanine (BG) can significantly decrease the MGMT activity of Mer+ cells through its ability to act as a substrate for the protein (Dolan et al, 1990a; Moschel et al, 1992; Pegg et al, 1993) . This property has been used to increase the Mer+ cell sensitivity to CENUs (Dolan et al, 1991; Baer et al, 1993; Mineura et al, 1994) . In vivo studies conducted on nude mice bearing Mer+ human colon or glioma tumours have shown that treatment with BG before administration of a bialkylating agent significantly inhibited tumour growth compared with animals treated with BG or a bialkylating agent alone (Dolan et al, 1990b; Friedman et al, 1992; Mitchell et al, 1992; Gerson et al, 1993) . A phase I clinical trial of BG with carmustine is in progress (Spiro et al, 1996) . Nevertheless, its clinical use can be problematic because of its very low water solubility, and new MGMT inhibitors have accordingly been developed that are more water soluble (Cussac et al, 1994a; Schold et al, 1996) .
To address this problem, we have synthesized N2-acetylguanosine and deoxyguanosine derivatives that are benzylated on the 06 position. The sugar moiety makes these species highly water soluble and the acetylation of the amine function should render pairing with the complementary base and the incorporation into (Madelmont et al, 1985; Bourrut et al, 1986; Mathe et al, 1992; Godeneche et al, 1994) . We have shown that both BNAG and BNAdG significantly increased the cytotoxicity of cystemustine towards M4Beu human melanoma tumour cells (Mer+) through the inhibition of MGMT. Preliminary in vivo anti-tumour tests on nude mice bearing M4Beu xenografts showed an increased inhibition of tumour growth by cystemustine in combination with BNAG but also an increased toxicity (Cussac et al, 1994a) . To investigate interactive phenomena between cystemustine and BNAG, a pharmacokinetic study of BNAG i.v. bolus was performed using 14C labelling Cussac et al, 1994b) . We showed that only 10% of the administered dose was metabolized and that the unchanged molecule had a rapid and wide distribution in all tissues except the central nervous system. Moreover, an enterohepatic cycle with a slow elimination rate extends the half-life of the molecule in the organism. From these pharmacokinetic characteristics, it is highly probable that MGMT inhibition, after an i.v. bolus, occurs promptly and is maintained for a long time after administration. Comparison with pharmacokinetic properties of cystemustine (Godeneche et al, 1987) indicates that a simultaneous i.v. injection of this CENU with BNAG should be the optimal administration schedule. In this work, our purpose is to compare the therapeutic index for the simultaneous administration of the BNAG/cystemustine combination with cystemustine alone in nude mice bearing resistant human melanoma. After measurement of the LD50 of BNAG, cystemustine and the combination of BNAG/cystemustine, the effectiveness of treatments at isotoxic doses are compared.
METHODS

Drugs
Cystemustine was synthesized by usual procedures (Madelmont et al, 1991) and BNAG was synthesized by procedures previously described monolayers in 75 cm2 culture flasks in Eagle's minimum essential medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (Sigma, St Louis, USA) and solutions of 5 ml of IOOX vitamins (Gibco), 5 ml of 100 mm sodium pyruvate (Gibco), S ml of IOOX non-essential amino acids (Gibco), 5 ml of 200 mM L-glutamine (Gibco) and 2 mg of gentamycin base (Gentalline, ScheringPlough, Levallois-Perret, France). Cells were grown at 37°C in a humidified atmosphere containing 5% carbon dioxide. M4Beu cell-doubling time was 24 h.
Toxicity assessment OFI female mice 5-7 weeks old (Iffa-Credo, L'Abresle, France) were randomly assigned to five groups of six mice (20-25 g) for each compound tested and treated once with cystemustine and/or BNAG by the i.p. route at 0.5 ml per 25 g. Both drugs were dissolved in sterile sodium chloride 0.9% with 2-7% of dimethylsulphoxide (DMSO), vehicle which showed no toxicity in the preliminary test (data not shown). The doses of cystemustine ranged from 40 to 82.8 mg kg-' or from 27.8 to 57.6 mg kg-' with a ratio of 1.2 between increasing doses to determine the LD50 of cystemustine alone or in combination with BNAG 40 mg kg-' respectively. The doses of BNAG ranged from 40 to 640 mg kg-' with a ratio of 2. Mice were weighed daily; when animals had loss of weight more than 25% or when they were expected to become moribund, according to the guidelines of UKCCCR (UKCCCR committee, 1988), they were sacrified by decapitation. On day 8 after administration, the LD50 was calculated using the simplified method of Behrens and Karber (1935) .
In vivo anti-tumour tests Swiss nu/nu female mice 6-7 weeks old (Iffa-Credo) were inoculated with 4 x 106 M4Beu cells by abdominal s.c. injection. One day later, animals were randomly assigned into five groups of eight mice and treated by i.v. route (tail vein) with cystemustine and/or BNAG at 0.3 ml per 25 g. Both drugs were dissolved in sterile sodium chloride 0.9% at several doses as indicated in the figures.
After treatment, animal weight and tumour dimensions were determined twice a week. Tumour dimensions were measured with callipers and tumour volume was calculated using the formula length x width2 x 0.5 (Dolan et al 1990b) .
At the end of each test, the animals were sacrificed and the xenografts were removed and weighed. Toxicity was assessed by survival and maximum body-weight loss. Tumour volume, tumour weight (only for the first test) and body-weight loss comparisons according to the treatment were performed using the Mann-Whitney U-test.
RESULTS
The acute toxicity of a single i.p. injection of BNAG alone, cystemustine alone or the combination of BNAG/cystemustine was evaluated on OFI female mice according to Behrens and Karber (Table 1) . BNAG showed no toxicity as no death nor loss of weight were observed at the maximal dose used (640 mg kg-').
The LD50 values of cystemustine with and without BNAG (40 mg kg-') on day 8 were 47.2 mg kg-' and 68.2 mg kg-' respectively. In both cases, the signs of toxicity were loss of weight, diarrhoea and asthenia. Maximal toxic effect occurred 6 days after injection with the different treatments. The ratios of maximal-tolerated dose and LD50 for cystemustine alone or in combination with BNAG were almost constant and were close to 1.44. To determine whether BNAG had a dose effect on the toxicity of 33.3 mg kg-' cystemustine, the toxicity of the combination was assessed with increased doses of BNAG. LD50 was obtained with 260 mg kg-' of BNAG.
To compare the therapeutic index of the combination with that of cystemustine alone, two in vivo anti-tumour tests were performed by i.v. route. The experimental model was Swiss nu/nu female mice bearing abdominal s.c. human melanoma M4Beu cells. This tumour line has a high MGMT activity (933 fmol mg-' of protein) and was strongly resistant to cystemustine (Cussac et al, 1994a) . The equitoxic doses of cystemustine alone or in combination with 40 or 50 mg kg-' BNAG were determined assuming the linear increase of cystemustine toxicity at all doses of BNAG. with BNAG was taken to be equal to 1.44, and this value was used to determine the calculated isotoxic dose.
In the first test (To), we chose a large dose to observe both tumour growth inhibition and toxic effect. Tumours appeared within 6 days in all groups of mice despite treatment and grew with different kinetics ( Figure IA) . No xenograft growth was observed with the cystemustine 18.75 mg kg-' and BNAG 50 mg kg-' (ToS) combination treatment. On day 30, when the mean tumour volume in the BNAG 50 mg kg-' (To2)-treated group reached approximately 1000 mm3, the test was stopped for all groups. T'umour volume and weight were used for the statistical comparison between the vehicle (To 1)-treated or cystemustine 27 mg kg-' dose (To4)-treated groups ( Table 2 ). The effect of the To2 treatment was not significantly different from that of the control (P = 0.38). Cystemustine 18.75 mg kg-' (To3) and To4 treatment was significantly different from control for tumour volume (P = 0.014 and P = 0.021 respectively). No significant dose-dependent difference was observed on tumour growth inhibition between the two treatments (To3 or To4) (P = 0.71). In contrast, the To5 treatment was significantly more effective in inhibiting tumour growth than the To3 or To4 treatments (P = 0.026 and P = 0.007 respectively).
The toxicity of the treatment was assessed by the number of deaths per group over the test, the maximum weight loss and the weight loss kinetics (Figure iB) . Tol and To2 treatment showed no toxicity. To3 and To4 were toxic with an increased To4 effect that was lethal on day 7 in one case. Toxic signs were the same as those described above. Association of BNAG with cystemustine demonstrated an increased toxic effect compared with cystemustine alone, but the number of dead mice and the maximum weight loss were the same in the two calculated isotoxic dose treatments To4 and To5.
In the second test (Th), we chose a lower dose of drug to monitor only the pharmacological effect of the treatment. We stopped this test for each group as soon as tumour growth was evident for all mice. Tumours appeared within 5 days in all groups. Tumour growth kinetics were different for each treatment ( Figure  2a ). Tumour began to grow within 9 days for vehicle (Thl)-and BNAG 40 mg kg-' (Th2)-treated mice. Cystemustine alone increased growth delay for the two tested doses. Mean tumour volume increased on day 16 for cystemustine 15 mg kg-' (Th3) treatment and on day 26 for cystemustine 21.6 mg kg-' (Th4); for both, the growth kinetics were equivalent. BNAG 40 mg kg-' and cystemustine 15 mg kg-' (ThS) treatment prevented tumour growth for up to 43 days as shown in Figure 2a . To assess whether the tumour was potentially able to grow, we kept the latter group of mice for an additional 20-day period. Tumours grew between day 49 and 63 for six out of the seven mice (data not shown). Tumour volumes on day 29 and on day 43 were used for statistical comparison (Table 3) . On day 29, tumour volumes were not significantly different between the Th2-and Thl-treated groups (P = 0.195). In contrast, cystemustine with or without BNAG treatments produced a lower volume than control (P = 0.003 for Th3 and Th4, and P < 0.001 for ThM). On day 43, the tumour volumes were different between the Th3-and Th4-treated groups, but not significantly (P = 0.235). The Th5-treated group had significantly smaller tumour volumes than the Th4-treated group (P = 0.002).
No toxicity was observed for treatments ThI, Th2 and Th3. The non-lethal toxicities of Th4 and Th5 were equal, with a mean maximum body weight loss close to 8%. Moreover, the loss of body weight kinetics was closely similar ( Figure 2B ).
DISCUSSION
The results described here clearly show that the administration of the water-soluble MGMT inhibitor BNAG enhances the therapeutic index of cystemustine, a CENU developed in our laboratory. In previous work, we have reported that BNAG is able to potentiate the efficiency of CENU on human melanoma cells in vitro and in vivo (Cussac et al, 1994a) . In vivo, we have shown an enhancement of the tumour growth-inhibitory effect and of cystemustine treatment toxicity by BNAG.
Here, we quantified this toxicity increase by studying the lethality of different treatments by cystemustine or BNAG alone Haematological toxic effects are dose limiting with CENUs and related methylating agents (Weiss and MacDonald, 1981) . Toxicological studies of 1,3-bis(2-chloroethyl)-1 -nitrosourea and BG combination single-i.v. dose treatments on mice and dogs show a dramatic increase of CENU myelosuppression by BG in both species Rodman et al, 1994) . Here, we detected no external sign of acute haemototoxicity, such as petechia, but further work is in progress to test the haematological effect of our combination.
To assess the efficiency of isotoxic i.v. doses of cystemustine alone or in combination with BNAG, we chose a previously described experimental model (Cussac et al, 1994a ) with repetitive i.v. injections on days 1, 5 and 9 after cell inoculation. We found a linear dose-effect relationship between cystemustine toxicity and BNAG dose in the i.p. results. The two doses of BNAG used (40 and 50 mg kg-') show that the ratio of 1.44 between isotoxic doses of cystemustine, alone or in combination, was conserved in both cases, confirming our suggested low risk of overdose with BNAG.
Regarding pharmacological effects, BNAG alone showed no effect on tumour growth, consistent with its lack of cytotoxicity in vitro, as previously described (Cussac et al, 1994a) . Tumour growth delay was observed with cystemustine alone but no significant dose-effect was demonstrated with the different low doses tested. Only the 27 mg kg' dose showed an improvement of the tumour growth inhibition with respect to the others. This result illustrates the limited efficiency of CENUs towards Mer+ tumour cells.
However, for both sets of isotoxic doses, we observed an increased tumour growth delay for the combination treatment. We chose a simultaneous i.v. injection of BNAG and cystemustine, according to BNAG pharmacokinetic characteristics in the mouse (Cussac et al, 1994a ). As BNAG is rapidly distributed from blood to tissues (distribution half-life = 13 min), we assumed that cellular uptake of BNAG would be achieved, and MGMT inhibition occurring before cystemustine would be able to react with its target. The tumour growth inhibition obtained with the combination supports this assumption. Hence, BNAG is the first MGMT inhibitor to display the ability to be effective as an adjuvant treatment with CENU after simultaneous administration by the i.v. route. Combination treatment of BNAG with other CENUs is conceivable and we are currently testing such combinations.
BNAG appears to be a good candidate for adjuvant treatment with CENUs. It offers four main advantages: (1) the absence of intrinsic toxicity; (2) linearity of its effect on toxicity, (3) relative weak activity of BNAG compared with BG for MGMT inhibition, limiting the risk of overdose in the adjuvant treatment; and (4) the possibility of simultaneous i.v. injection with associated CENU.
